Medicx Fund Regulatory News (MXF)

For immediate release

24 August 2017

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Scrip Calculation Price for the September 2017 Dividend in relation to the Scrip Dividend Scheme

On 17 May 2010 the Board of MedicX Fund Limited announced an opportunity for qualifying Shareholders to receive relevant dividends in new ordinary shares instead of in cash (the "Scheme").

In relation to the dividend for the period 1 April 2017 to 30 June 2017 payable on 28 September 2017 (the "September 2017 Dividend"), the price of a new ordinary share in relation to the Scrip Dividend Scheme (the "Scrip Calculation Price") has been set at 89.55 pence. This is the average of the closing middle market quotations for the Company's ordinary shares for the five consecutive business days commencing on the ex-dividend date of 17 August 2017.

In order to be valid, Mandate forms must be received by the Company's registrars, Capita Asset Services, (or CREST instructions entered) by no later than 5.00 p.m. on 7 September 2017 (the "Mandate Delivery Deadline") in order for elections under the Scrip Dividend Scheme to be effective in relation to the September 2017 Dividend. The Company mailed, on 22 August 2017, personalised Mandate Forms to Shareholders new on the Register since 20 May 2017 and before 18 August 2017 (the "Record Date"). Other Shareholders can use their Mandate Forms issued for previous scrip dividends offered, or obtain Mandate Forms from Capita Asset Services.

Mandate Forms remain valid for all Relevant Dividends where a Scrip Dividend Alternative is offered, until cancelled. Therefore, Shareholders who have previously completed a Mandate Form but no longer wish to receive a Scrip Dividend should write to Capita Asset Services, Corporate Actions, The Registry, 34 Beckenham Road, Beckenham, Kent, BR3 4TU, by no later than 5.00 p.m. on the Mandate Delivery Deadline for the Relevant Dividend to inform them that they wish to revoke the election and receive a cash dividend.

Shareholders who do not wish to receive a Scrip Dividend Alternative and have not previously completed a Mandate Form need take no further action and will receive a cash dividend in respect of the September 2017 Dividend in the usual way. The payment date in respect of the September 2017 Dividend is 28 September 2017.

Shareholders who have any questions regarding the Scrip Dividend Scheme should contact the Capita Asset Services helpline on 0371 664 0321*.

*Calls made to this number are charged at 12 pence per minute plus network charges. Lines are open 8.30 a.m. to 5.30 p.m. (London time) Monday to Friday (except Bank Holidays).

End

For further information please contact:

MedicX Fund +44 (0) 1481 723 450

David Staples, Chairman

Octopus Healthcare Group +44 (0) 20 3142 4820

Mike Adams, Chief Executive Officer

Buchanan +44 (0) 20 7466 5000

Charles Ryland/Vicky Hayns

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", "MedicX Fund", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom and Ireland, listed on the London Stock Exchange, with a portfolio comprising 156 properties.

The Investment Adviser to the Company is Octopus Healthcare Adviser Ltd, which is part of the Octopus Healthcare group. Octopus Healthcare invests in and develops properties as well as creating partnerships to deliver innovative healthcare buildings to improve the health, wealth and wellbeing of the UK. It currently manages over £1.1 billion of healthcare investments across a number of platforms, with a focus on five core areas: GP surgeries, care homes, special education schools, retirement housing and private hospitals. Octopus Healthcare is part of the Octopus group, a fast-growing UK fund management business with leading positions in several specialist sectors including healthcare property, energy, property finance and smaller company investing. Octopus manages £7 billion of funds for more than 50,000 retail and institutional investors as well as supplying energy to more than 100,000 customers.

Octopus Healthcare Adviser Ltd is authorised and regulated by the Financial Conduct Authority.

The Company's website address is www.medicxfund.com. Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website), nor the contents of any website accessible from hyperlinks within this announcement, are incorporated into, or forms part of, this announcement.

The Company's Legal Entity Identifier is 2138008POF35FTNFCB25